Immunotherapy for non-small cell lung cancer: Current concepts and clinical trials

European Journal of Cardio-thoracic Surgery

Volumn 49, Issue 5, 2016, Pages 1324-1333

  Mayor, Marissa ^a   Yang, Neng ^a   Sterman, Daniel ^b   Jones, David R ^a   Adusumilli, Prasad S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NEW YORK UNIVERSITY   (United States)

Author keywords

Adoptive cell therapy; Antibody therapy; Chimeric antigen receptor; Lung cancer; PD 1 PD L1 blockade

Indexed keywords

CANCER VACCINE; CHIMERIC ANTIGEN RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOTOXIN; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR; SCATTER FACTOR RECEPTOR; T LYMPHOCYTE RECEPTOR; VASCULOTROPIN;

ADOPTIVE IMMUNOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELL THERAPY; CYTOKINE INDUCED KILLER CELL; GENETIC ENGINEERING; HUMAN; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NATURAL KILLER CELL; NON SMALL CELL LUNG CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THORACIC SURGEON; TUMOR ASSOCIATED LEUKOCYTE; ANIMAL; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL (TOPIC); IMMUNOTHERAPY; LUNG NEOPLASMS; MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; GENETIC ENGINEERING; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; MICE;

EID: 84965117367     PISSN: 10107940     EISSN: 1873734X     Source Type: Journal    
DOI: 10.1093/ejcts/ezv371     Document Type: Review

References (77)

1. Pirker R, Pereira JR, von Pawel J, Krzakowski M, Ramlau R, Park K et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 2012;13:33-42.
2. Yang ZY, Liu L, Mao C, Wu XY, Huang YF, Hu XF et al. Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer. Cochrane Database Syst Rev 2014;11: CD009948.
3. Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol 2015;16:763-74.
4. Paz-Ares L, Mezger J, Ciuleanu TE, Fischer JR, von Pawel J, Provencio M et al. Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. Lancet Oncol 2015;16:328-37.
5. Inami K, Kajino K, Abe M, Hagiwara Y, Maeda M, Suyama M et al. Secretion of N-ERC/mesothelin and expression of C-ERC/mesothelin in human pancreatic ductal carcinoma. Oncol Rep 2008;20:1375-80.
6. Spigel DR, Edelman MJ, O'Byrne K, Paz-Ares L, Shames DS, Yu W et al. Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial. J Clin Oncol 2014;32(5s suppl):abstr 8000.
7. Gozdzik-Spychalska J, Szyszka-Barth K, Spychalski L, Ramlau K, Wojtowicz J, Batura-Gabryel H et al. C-MET inhibitors in the treatment of lung cancer. Curr Treat Options Oncol 2014;15:670-82.
8. Tan E, Park K, Lim WT, Ahn M, Ng QS, Ahn JS et al. Phase Ib study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients ( pts) with NSCLC. J Clin Oncol 2011;29:abstr 7571.
9. Chaft JE, Rusch V, Ginsberg MS, Paik PK, Finley DJ, Kris MG et al. Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers. J Thorac Oncol 2013;8:1084-90.
10. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50.
11. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27:1227-34.
12. Reck M, Barlesi F, Crino L, Henschke CI, Isla D, Stiebeler S et al. Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts. Ann Oncol 2012;23:1111-20.
13. Garon EB, Ciuleanu T-E, Arrieta O, Prabhash K, Syrigos KN, Goksel T et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for secondline treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 2014;384:665-73.
14. Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, Riley JL et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002;168:4272-6.
15. Grosso JF, Jure-Kunkel MN. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun 2013;13:5.
16. Yuan J, Page DB, Ku GY, Li Y, Mu Z, Ariyan C et al. Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy. Cancer Immun 2010;10:1.
17. Chen H, Liakou CI, Kamat A, Pettaway C, Ward JF, Tang DN et al. Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci USA 2009;106:2729-34.
18. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
19. Zatloukal P, Heo DS, Park K, Kang J, Butts C, Bradford D et al. Randomized phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care (BSC) following first-line platinum-based therapy in patients ( pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2009;27(15s suppl):abstr 8071.
20. Tomasini P, Khobta N, Greillier L, Barlesi F. Ipilimumab: its potential in non-small cell lung cancer. Ther Adv Med Oncol 2012;4:43-50.
21. Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012;30: 2046-54.
22. Lacouture ME, Wolchok JD, Yosipovitch G, Kahler KC, Busam KJ, Hauschild A. Ipilimumab in patients with cancer and the management of dermatologic adverse events. J Am Acad Dermatol 2014;71:161-9.
23. Zhang Y, Huang S, Gong D, Qin Y, Shen Q. Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer. Cell Mol Immunol 2010;7: 389-95.
24. Nivolumab approved for lung cancer. Cancer Discov 2015;5:OF1.
25. Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 2015;16:257-65.
26. Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2015;33: 2004-12.
27. Ribas A, Hodi FS, Kefford R, Hamid O, Daud A, Wolchok JD et al. Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). J Clin Oncol 2014;32(5s suppl):abstr LBA9000.
28. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372:2018-28.
29. Papadimitrakopoulou V, Patnaik A, Borghaei H, Stevenson J, Gandhi L, Gubens MA et al. Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced nonsmall cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C. J Clin Oncol 2015;33(suppl):abstr 8031.
30. Zhang Y,Wang L, Li Y, Pan Y,Wang R, Hu H et al. Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. OncoTargets Ther 2014; 7:567-73.
31. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65.
32. Ryder M, Callahan M, Postow MA, Wolchok J, Fagin JA. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer 2014;21:371-81.
33. Rizvi NA, Brahmer JR, Ou SI, Segal NH, Khleif S, Hwu W et al. Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). J Clin Oncol 2015;33:abstr 8032.
34. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
35. Pan ZK, Ye F, Wu X, An HX, Wu JX. Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis. J Thorac Dis 2015;7: 462-70.
36. Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M et al. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest 2014;94:107-16.
37. Ansen S, Schultheis AM, Hellmich M, Zander T, Brockmann M, Stoelben E et al. PD-L1 expression and genotype in non-small cell lung cancer (NSCLC). J Clin Oncol 2014;32(5s suppl):abstr 7517.
38. Spira A, Park K, Mazières J. Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR). J Clin Oncol 2015;33:abstr 8010.
39. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348:124-8.
40. Lynch TJ Jr, Lambert JM, Coral F, Shefner J, Wen P, Blattler WA et al. Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin. J Clin Oncol 1997;15:723-34.
41. Frankel AE, Woo JH, Ahn C, Foss FM, Duvic M, Neville PH et al. Resimmune-an anti-CD3epsilon recombinant immunotoxin induces durable remissions in cutaneous T cell lymphoma patients. Haematologica 2015; 100:794-800.
42. Garland L, Gitlitz B, Ebbinghaus S, Pan H, de Haan H, Puri RK et al. Phase I trial of intravenous IL-4 pseudomonas exotoxin protein (NBI-3001) in patients with advanced solid tumors that express the IL-4 receptor. J Immunother 2005;28:376-81.
43. Fan D, Yano S, Shinohara H, Solorzano C, Van Arsdall M, Bucana CD et al. Targeted therapy against human lung cancer in nude mice by high-affinity recombinant antimesothelin single-chain Fv immunotoxin. Mol Cancer Ther 2002;1:595-600.
44. Kachala SS, Bograd AJ, Villena-Vargas J, Suzuki K, Servais EL, Kadota K et al. Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma. Clin Cancer Res 2014;20:1020-8.
45. Mellstedt H, Vansteenkiste J, Thatcher N. Vaccines for the treatment of non-small cell lung cancer: investigational approaches and clinical experience. Lung Cancer 2011;73:11-7.
46. Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE et al. Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol 2015;10:S1-S63.
47. Bazhenova L, Giaccone G, Nemunaitis JJ, Juhász E, Ramlau R, van den Heuvel MM et al. An international, multicenter, randomized, double-blind phase III study of maintenance belagenpumatucel-l in non-small cell lung cancer (NSCLC): updated analysis of patients enrolled within 12 weeks of completion of chemotherapy. J Clin Oncol 2014;32(5s suppl):abstr 8056.
48. Nemunaitis J, Jahan T, Ross H, Sterman D, Richards D, Fox B et al. Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer. Cancer Gene Ther 2006;13: 555-62.
49. Tyagi P, Mirakhur B. MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin Lung Cancer 2009;10:371-4.
50. Vansteenkiste J, Zielinski M, Linder A, Dahabreh J, Gonzalez EE, Malinowski W et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. J Clin Oncol 2013;31:2396-403.
51. GlaxoSmithKline. Update on phase III clinical trial of investigational MAGE-A3 antigen-specific cancer immunotherapeutic in non-small cell lung cancer 2014.
52. Kao CJ, Wurz GT, Monjazeb AM, Vang DP, Cadman TB, Griffey SM et al. Antitumor effects of cisplatin combined with tecemotide immunotherapy in a human MUC1 transgenic lung cancer mouse model. Cancer Immunol Res 2014;2:581-9.
53. Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol 2014;15:59-68.
54. Cuppens K, Vansteenkiste J. Vaccination therapy for non-small-cell lung cancer. Curr Opin Oncol 2014;26:165-70.
55. Quoix E, Ramlau R, Westeel V, Papai Z, Madroszyk A, Riviere A et al. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial. Lancet Oncol 2011;12:1125-33.
56. Yanagawa H, Haku T, Hiramatsu K, Nokihara H, Takeuchi E, Yano S et al. Intrapleural instillation of interferon gamma in patients with malignant pleurisy due to lung cancer. Cancer Immunol Immunother 1997;45:93-9.
57. Sterman DH, Recio A, Haas AR, Vachani A, Katz SI, Gillespie CT et al. A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions. Mol Ther 2010;18:852-60.
58. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008;8:299-308.
59. Kakimi K, Matsushita H, Murakawa T, Nakajima J. ?d T cell therapy for the treatment of non-small cell lung cancer. Transl Lung Cancer Res 2014;3: 23-33.
60. Shi SB, Ma TH, Li CH, Tang XY. Effect of maintenance therapy with dendritic cells: cytokine-induced killer cells in patients with advanced nonsmall cell lung cancer. Tumori 2012;98:314-9.
61. Li R, Wang C, Liu L, Du C, Cao S, Yu J et al. Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study. Cancer Immunol Immunother 2012;61:2125-33.
62. Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 2015;33:540-9.
63. Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014;6:224ra25.
64. Iliopoulou EG, Kountourakis P, Karamouzis MV, Doufexis D, Ardavanis A, Baxevanis CN et al. A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunol Immunother 2010;59:1781-9.
65. Zhang G, Zhao H, Wu J, Li J, Xiang Y, Wang G et al. Adoptive immunotherapy for non-small cell lung cancer by NK and cytotoxic T lymphocytes mixed effector cells: retrospective clinical observation. Int Immunopharmacol 2014;21:396-405.
66. Yang YJ, Park JC, Kim HK, Kang JH, Park SY. A trial of autologous ex vivo-expanded NK cell-enriched lymphocytes with docetaxel in patients with advanced non-small cell lung cancer as second-or third-line treatment: phase IIa study. Anticancer Res 2013;33:2115-22.
67. Thomas A, Chen Y, Steinberg S, Luo J, Pack S, Raffeld M et al. High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis. Oncotarget 2015;6:11694-703.
68. Servais EL, Colovos C, Rodriguez L, Bograd AJ, Nitadori J, Sima C et al. Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients. Clin Cancer Res 2012;18:2478-89.
69. Rizk NP, Servais EL, Tang LH, Sima CS, Gerdes H, Fleisher M et al. Tissue and serum mesothelin are potential markers of neoplastic progression in Barrett's associated esophageal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2012;21:482-6.
70. Tozbikian G, Brogi E, Kadota K, Catalano J, Akram M, Patil S et al. Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival. PLoS One 2014;9:e114900.
71. Villena-Vargas J, Adusumilli PS. Mesothelin-targeted immunotherapies for malignant pleural mesothelioma. Ann Cardiothorac Surg 2012;1:466-71.
72. Adusumilli PS, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, Plotkin J et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med 2014;6:261ra151.
73. Suzuki K, Kadota K, Sima CS, Nitadori J, Rusch VW, Travis WD et al. Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor beta2 (IL-12Rbeta2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence. J Clin Oncol 2013;31:490-8.
74. Suzuki K, Kachala SS, Kadota K, Shen R, Mo Q, Beer DG et al. Prognostic immune markers in non-small cell lung cancer. Clin Cancer Res 2011;17: 5247-56.
75. Goc J, Germain C, Vo-Bourgais TK, Lupo A, Klein C, Knockaert S et al. Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells. Cancer Res 2014;74:705-15.
76. Crittenden M, Kohrt H, Levy R, Jones J, Camphausen K, Dicker A et al. Current clinical trials testing combinations of immunotherapy and radiation. Semin Radiat Oncol 2015;25:54-64.
77. de Biasi AR, Villena-Vargas J, Adusumilli PS. Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence. Clin Cancer Res 2014;20:5384-91.